![](/img/cover-not-exists.png)
A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin
Zheng, Yi, Tu, Xiaoxuan, Zhao, Peng, Jiang, Weiqin, Liu, Lulu, Tong, Zhou, Zhang, Hangyu, Yan, Cong, Fang, Weijia, Wang, WeilinLanguage:
english
Journal:
British Journal of Cancer
DOI:
10.1038/s41416-018-0138-2
Date:
June, 2018
File:
PDF, 450 KB
english, 2018